Skip to content

Prevention of Ischemia in Aneurysmal Subarachnoid Hemorrhage Through Remote Ischemic Preconditioning

Remote Ischemic Preconditioning (RIPC) and Aneurysmal Subarachnoid Hemorrhage (SAH)

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07761520
Acronym
HMA
Enrollment
140
Registered
2026-08-12
Start date
2026-09-01
Completion date
2029-09-01
Last updated
2026-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal Subarachnoid Hemorrhage

Keywords

Aneurysmal Subarachnoid Hemorrhage (aSAH), Remote Ischemic Preconditioning (RIPC)

Brief summary

Aneurysmal subarachnoid hemorrhage (SAH) is a severe form of stroke caused by bleeding around the brain. Despite early treatment of the initial hemorrhage, many patients develop delayed cerebral ischemia several days later, which is a major cause of neurological disability, cognitive impairment, and mortality. Current preventive and therapeutic strategies are only partially effective, highlighting the need for new treatment approaches. This study investigates a simple, non-invasive technique called remote ischemic preconditioning (RIPC). RIPC consists of brief, repeated cycles of limb ischemia and reperfusion induced by a blood pressure cuff. RIPC is thought to activate endogenous protective mechanisms that may improve the brain's tolerance to ischemia. Although beneficial effects have been reported in experimental models and cardiovascular diseases, its clinical efficacy in aneurysmal SAH remains uncertain. In this randomized, controlled, single-blinded, multicenter study, adult patients admitted with aneyrysmal SAH will be randomly assigned to receive RIPC or a sham procedure. The RIPC group will undergo cycles of brief lower-limb ischemia using a pressure cuff, while the sham group will receive an identical procedure without inducing ischemia. Patients and neurologists assessing outcomes will remain blinded to group allocation. The intervention will be performed every two days from day 2 to day 10 after hemorrhage. Neurological outcome will be assessed at 3 months using the modified Rankin Scale. Secondary outcomes include mortality at 3 months, long-term neurological and cognitive function outcomes at 12 months, and the incidence of adverse events related to the procedure. If effective, RIPC could become a simple, low-cost, widely accessible method to reduce disability after SAH. The results may help improve future treatment strategies for this severe condition.

Interventions

PROCEDURERemote Ischemic Preconditioning

Three cycles of lower-limb ischemia and reperfusion using a blood pressure cuff inflated to 20 mmHg above systolic blood pressure for 5 minutes followed by 5 minutes of reperfusion. The procedure is performed every two days from day 2 to day 10 after aneurysmal subarachnoid hemorrhage.

Identical procedure to the experimental arm, except the cuff is inflated to only 30 mmHg, insufficient to induce ischemia, giving the sensation of pressure without therapeutic effect. Performed every two days from day 2 to day 10 post-hemorrhage.

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age over 18 years * Hospitalization for aneurysmal subarachnoid hemorrhage confirmed by CT scan and/or lumbar puncture * Confirmation of intracranial aneurysm by CT angiography and/or cerebral angiography * Written informed consent obtained from the patient or legal representative * Affiliation to a social security system

Exclusion criteria

* Skin, orthopedic, or vascular conditions of the limbs contraindicating ischemic preconditioning (e.g., ulcers, fractures, deep vein thrombosis) * Pregnancy * Withdrawal of informed consent

Design outcomes

Primary

MeasureTime frameDescription
Neurological Functional Outcome at 3 Months (mRS)3 months (+/- 15 days) post-aneurysmal subarachnoid hemorrhageAssessment of neurological disability and dependency using the modified Rankin Scale (mRS) performed by a blinded neurologist. The mRS is a 6-point scale (0 to 5), with 5 being a severe disability.

Secondary

MeasureTime frameDescription
Evaluation of mortality at 3 MonthsFrom day 0 to 3 months post-hemorrhageComparison of all-cause mortality between the RIPC group and the sham group
Long-term Neurological Outcome at 12 Months (mRS)12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhageAssessment of long-term neurological disability and dependency using the modified Rankin Scale (mRS) performed by a blinded neurologist. The mRS is a 6-point scale (0 to 5), with 5 being a severe disability.
Evaluation of Cognitive Function at 12 months (MMSE)12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhageEvaluation of cognitive performance assessed using the Mini-Mental State Examination (MMSE). The MMSE score ranks from 0 to 30, with 30 being a normal congnitive performance and 0 serious cognitive impairments.
Evaluation of Cognitive Function at 12 months (MoCA)12 months (+/- 30 days) post-aneurysmal subarachnoid hemorrhageEvaluation of cognitive performance assessed using the Montreal Cognitive Assessment (MoCA). The MoCA is scored out of 30 points, with high scores suggesting mild or no cognitive impairments, and low scores severe cognitive impairments.
Safety OutcomesFrom day 0 until 12 months post-aneurysmal subarachnoid hemorrhage.Incidence, nature, and severity of adverse events and serious adverse events occurring during the study period.

Contacts

CONTACTJacques Sedat, MD
sedat.j@chu-nice.fr+33 4 92 03 38 07
CONTACTEve Ledoux
ledoux.e@chu-nice.fr+33 4 92 03 27 29

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 13, 2026